ILC: J&J's RNAi suppresses hepatitis B for 48 weeks after last dose
Johnson & Johnson has presented clinical trial data linking short-term treatment with RNAi therapy JNJ-3989 to sustained reductions in markers of hepatitis B infection. The data drop comes as J&J runs 48-week phase 2b trials of the Arrowhead-partnered drug in the pursuit of a functional cure.
28 Aug 2020 ... Johnson & Johnson said new data support the evaluation of longer durations of treatment with JNJ-3989. (Raysonho/CC0). Share Facebook ...